CCCC
C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.39
−0.73%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.21
- Revenue estimate
- $8.8M
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.18
- EPS estimate
- -$0.23
- Revenue actual
- $6.6M
- Revenue estimate
- $4.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +12.4%
- Revenue beats (12Q)
- 8
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.23 | -$0.18 | Beat 20.49% | $6.6M |
| May 12, 2026 | -$0.25 | -$0.20 | Beat 20.20% | $6.2M |
| Nov 6, 2025 | -$0.47 | -$0.44 | Beat 6.38% | $11.2M |
| Aug 7, 2025 | -$0.38 | -$0.37 | Beat 2.63% | $6.5M |
| Feb 27, 2025 | -$0.44 | -$0.49 | Miss -11.36% | $5.2M |
| Oct 31, 2024 | -$0.40 | -$0.35 | Beat 12.50% | $15.4M |
| Aug 1, 2024 | -$0.37 | -$0.26 | Beat 29.73% | $12.0M |
| Feb 22, 2024 | -$0.67 | -$0.68 | Miss -1.49% | $3.3M |
| Nov 1, 2023 | -$0.65 | -$0.55 | Beat 15.38% | $11.1M |
| May 4, 2023 | -$0.78 | -$0.71 | Beat 8.97% | $3.8M |
| Feb 23, 2023 | -$0.72 | -$0.76 | Miss -5.56% | $2.9M |
| Nov 3, 2022 | -$0.65 | -$0.65 | In line | $6.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026